SG10201913953UA - Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids - Google Patents
Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acidsInfo
- Publication number
- SG10201913953UA SG10201913953UA SG10201913953UA SG10201913953UA SG10201913953UA SG 10201913953U A SG10201913953U A SG 10201913953UA SG 10201913953U A SG10201913953U A SG 10201913953UA SG 10201913953U A SG10201913953U A SG 10201913953UA SG 10201913953U A SG10201913953U A SG 10201913953UA
- Authority
- SG
- Singapore
- Prior art keywords
- reversal
- disease
- prevention
- treatment
- fatty acids
- Prior art date
Links
- 235000014113 dietary fatty acids Nutrition 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229930195729 fatty acid Natural products 0.000 title 1
- 239000000194 fatty acid Substances 0.000 title 1
- 150000004665 fatty acids Chemical class 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562236702P | 2015-10-02 | 2015-10-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201913953UA true SG10201913953UA (en) | 2020-03-30 |
Family
ID=58428002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913953UA SG10201913953UA (en) | 2015-10-02 | 2016-10-03 | Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids |
Country Status (17)
Country | Link |
---|---|
US (3) | US10537541B2 (en) |
EP (1) | EP3355879A4 (en) |
JP (2) | JP2018529779A (en) |
KR (1) | KR20180098222A (en) |
CN (2) | CN108430466A (en) |
AU (2) | AU2016331314A1 (en) |
BR (1) | BR112018006687A2 (en) |
CA (1) | CA3000842A1 (en) |
CL (1) | CL2018000835A1 (en) |
CO (1) | CO2018004576A2 (en) |
CR (1) | CR20180246A (en) |
EA (1) | EA201890859A1 (en) |
HK (1) | HK1259031A1 (en) |
IL (2) | IL258476B2 (en) |
MX (1) | MX2018004043A (en) |
SG (1) | SG10201913953UA (en) |
WO (1) | WO2017059451A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009134383A2 (en) * | 2008-05-01 | 2009-11-05 | Complexa Inc. | Vinyl substituted fatty acids |
US20140024713A1 (en) | 2008-06-19 | 2014-01-23 | University Of Utah Research Foundation | Use of nitrated lipids for treatment of side effects of toxic medical therapies |
ES2971969T3 (en) | 2015-07-07 | 2024-06-10 | H Lundbeck As | PDE9 Inhibitors with Imidazopyrazinone Backbone for the Treatment of Peripheral Diseases |
KR20180098222A (en) * | 2015-10-02 | 2018-09-03 | 컴플렉사, 인코포레이티드 | Prevention, treatment and reversal of diseases using therapeutically effective amounts of activated fatty acids |
CN117843645A (en) | 2018-05-25 | 2024-04-09 | 伊马拉公司 | Monohydrate and crystalline forms of PDE9 inhibitors |
CN111229120B (en) * | 2018-11-29 | 2022-01-07 | 中国石油化工股份有限公司 | Mixed system containing fatty acid type surfactant and preparation method thereof |
CN111229117B (en) * | 2018-11-29 | 2022-01-04 | 中国石油化工股份有限公司 | Mixed system containing fatty acid type surfactant and preparation method thereof |
FR3092968B1 (en) * | 2019-02-22 | 2021-05-21 | Microphyt | DIETARY SUPPLEMENT |
CN110157792A (en) * | 2019-04-22 | 2019-08-23 | 中山大学孙逸仙纪念医院 | Serum excretion body has_circ_0004771 is preparing the application in alcohol dependence syndrome diagnostic reagent |
WO2021242758A1 (en) * | 2020-05-26 | 2021-12-02 | Imara Inc. | Improved nitro-fatty acid oral dose regimens |
WO2023014748A1 (en) * | 2021-08-03 | 2023-02-09 | Imara Inc. | Nitrated fatty acids for the treatment of sickle cell disorders |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB587992A (en) | 1944-12-11 | 1947-05-12 | Charles William Scaife | Improvements in and relating to the production of organic nitrogen compounds |
US3578687A (en) | 1968-01-30 | 1971-05-11 | Texaco Inc | Process for producing 4-nitroalkanoic acids |
US3819561A (en) | 1970-10-23 | 1974-06-25 | Aerojet General Co | Wetting agents for non-aqueous dispersions |
JPS5313608B2 (en) | 1972-06-16 | 1978-05-11 | ||
JPS5318013B2 (en) | 1973-03-19 | 1978-06-13 | ||
US4599430A (en) | 1981-12-21 | 1986-07-08 | The Standard Oil Company | Nitrogenation of hydrocarbons, including the production of maleimide |
JPS62132804A (en) | 1985-12-05 | 1987-06-16 | Aguro Kanesho Kk | Plant growth regulator |
US5412137A (en) | 1993-06-07 | 1995-05-02 | Sandoz Ltd. | Process for preparing phosphinyloxy propanaminium inner salt derivatives |
CA2202503C (en) | 1994-10-13 | 2008-07-15 | Antonio Ferrante | Modified polyunsaturated fatty acids |
US5919816A (en) | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
US5741211A (en) | 1995-10-26 | 1998-04-21 | Medtronic, Inc. | System and method for continuous monitoring of diabetes-related blood constituents |
GB9618420D0 (en) | 1996-09-04 | 1996-10-16 | Scotia Holdings Plc | Fatty acid treatment |
US6187747B1 (en) | 1997-09-08 | 2001-02-13 | Panacea Biotech Limited | Pharmaceutical composition comprising cyclosporin |
WO1999022719A1 (en) | 1997-10-30 | 1999-05-14 | Morishita Jintan Co., Ltd. | Capsular preparation containing unsaturated fatty acid or derivative thereof and process for producing the same |
AU5565599A (en) | 1998-08-14 | 2000-03-06 | Dante J. Marciani | Chemically modified saponins and the use thereof as adjuvants |
IL145712A0 (en) | 1999-04-01 | 2002-07-25 | Esperion Therapeutics Inc | Ether compounds, compositions, and uses thereof |
WO2001006983A2 (en) | 1999-07-22 | 2001-02-01 | Incell Corporation, Llc | Fatty acids to minimize cancer therapy side effects |
SE9903028D0 (en) | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
AUPQ291499A0 (en) | 1999-09-17 | 1999-10-07 | Women's And Children's Hospital Adelaide | Novel nitro and sulphur containing compounds |
US6346231B1 (en) | 1999-10-06 | 2002-02-12 | Joar Opheim | Flavored gelatin capsule and method of manufacture |
US20010037598A1 (en) | 1999-12-14 | 2001-11-08 | Suppes Galen J. | Process for producing cetane improvers from triglycerides |
WO2001060778A2 (en) | 2000-02-16 | 2001-08-23 | The Brigham And Women's Hospital, Inc. | Aspirin-triggered lipid mediators |
AR030416A1 (en) | 2000-04-13 | 2003-08-20 | Pharmacia Corp | HALOGENATED DERIVATIVE COMPOUND OF HEPTENOIC ACID 2-AMINO-3,4, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE IN THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT AS AN INHIBITOR OF SYNTHETIC NITRIC OXIDE |
AR034120A1 (en) | 2000-04-13 | 2004-02-04 | Pharmacia Corp | HALOGENATED DERIVATIVE COMPOUND OF HEPTENOIC ACID 2-AMINO-4,5, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND THE USE OF SUCH COMPOUND AND SUCH COMPOSITION IN THE MANUFACTURE OF A MEDICINAL PRODUCT TO INHIBIT OR MODULATE NITRIC ACID SYNTHESIS |
AR032318A1 (en) | 2000-04-13 | 2003-11-05 | Pharmacia Corp | HALOGENATED DERIVATIVE COMPOUND OF HEPTENOIC ACID 2-AMINO-5,6; PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE IN THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT AS AN INHIBITOR OF NITRICAL SYNTHEASE OXIDE |
CA2412232C (en) | 2000-06-28 | 2010-03-30 | Zambon Group S.P.A. | Process for the preparation of nitroalkenes |
AR031129A1 (en) | 2000-09-15 | 2003-09-10 | Pharmacia Corp | DERIVATIVES OF ACIDS 2-AMINO-2-ALQUIL-4-HEXENOICO AND -HEXINOICO USEFUL AS INHIBITORS OF NITRICO OXIDE SYNTHEASE |
DE60223670T2 (en) | 2001-04-18 | 2008-03-06 | Prometic Biosciences Inc., Mont-Royal | Fatty acids as factors for survival and activation of neutrophils. |
US7105556B2 (en) | 2001-05-30 | 2006-09-12 | Bristol-Myers Squibb Company | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
WO2002102364A1 (en) | 2001-06-18 | 2002-12-27 | Yamada, Sachiko | Pparg agonistic medicinal compositions |
CN1571672A (en) | 2001-08-17 | 2005-01-26 | 匹兹堡大学 | Administration of estradiol metabolites for the treatment or prevention of obesity, metabolic syndrome, diabetes, and vascular and renal disorders |
GB0123961D0 (en) | 2001-10-05 | 2001-11-28 | Astrazeneca Ab | Process and intermediates |
US20030166716A1 (en) | 2001-11-06 | 2003-09-04 | Serhan Charles N. | Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases |
US7759395B2 (en) | 2002-08-12 | 2010-07-20 | The Brigham And Women's Hospital, Inc. | Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma |
CA2875522A1 (en) | 2002-08-20 | 2004-03-04 | Philera New Zealand Limited | Dosage forms and related therapies |
AU2003272738B2 (en) | 2002-09-27 | 2010-04-01 | Martek Biosciences Corporation | Docosahexaenoic acid for improved glycemic control |
US7166575B2 (en) | 2002-12-17 | 2007-01-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity |
WO2005016864A1 (en) | 2003-07-29 | 2005-02-24 | The Arizona Disease Control Research Commission | Conjugated nitro alkene anticancer agents based on isoprenoid metabolism |
US20050136103A1 (en) | 2003-09-17 | 2005-06-23 | Ben-Sasson Shmuel A. | Compositions capable of facilitating penetration across a biological barrier |
US7935365B2 (en) | 2003-10-22 | 2011-05-03 | Enzymotec, Ltd. | Glycerophospholipids for the improvement of cognitive functions |
WO2005073164A1 (en) | 2004-01-30 | 2005-08-11 | Peplin Biolipids Pty Ltd | Therapeutic and carrier molecules |
CA2563533C (en) | 2004-04-15 | 2013-10-01 | Shmuel A. Ben-Sasson | Compositions capable of facilitating penetration across a biological barrier |
US7776916B2 (en) * | 2004-04-28 | 2010-08-17 | The Uab Research Foundation | Nitrated lipids and methods of making and using thereof |
NZ553263A (en) | 2004-07-19 | 2010-06-25 | Biocon Ltd | Insulin-oligomer conjugates, formulations and uses thereof |
EP1772149A1 (en) | 2004-07-27 | 2007-04-11 | Kowa Company. Ltd. | Drug for prevention or treatment of diabetes |
EP1824809A4 (en) | 2004-11-19 | 2010-03-03 | Martek Biosciences Corp | Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same |
US20070032420A1 (en) | 2005-02-09 | 2007-02-08 | Entelos, Inc. | Treating diabetes with glucagon-like peptide-1 secretagogues |
US9274129B2 (en) | 2006-05-31 | 2016-03-01 | Lpath, Inc. | Methods and reagents for detecting bioactive lipids |
US20090264483A1 (en) | 2006-07-14 | 2009-10-22 | Cedars-Sinai Medical Center | METHODS OF USING PPAR-gamma AGONISTS AND CASPASE-DEPENDENT CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER |
CN101528218A (en) | 2006-07-19 | 2009-09-09 | 雷索维克斯药品公司 | Compositions and methods for the treatment of mucositis |
EP2120920A4 (en) | 2007-02-20 | 2011-06-15 | Martek Biosciences Corp | Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same |
DK2180787T3 (en) | 2007-08-01 | 2014-02-03 | Univ Pittsburgh | NITROOLIC ACID MODULATION OF TYPE II DIABETES |
AU2008301895A1 (en) | 2007-09-14 | 2009-03-26 | Resolvyx Pharmaceuticals, Inc. | Oxylipin compounds for treating autoimmune diseases |
EP2271929B1 (en) | 2008-04-18 | 2015-11-25 | The University of Utah Research Foundation | Use of nitrated lipids for treatment of lipid disorders and obesity, and lipid- and obesity-related conditions |
WO2009134383A2 (en) | 2008-05-01 | 2009-11-05 | Complexa Inc. | Vinyl substituted fatty acids |
WO2009149496A1 (en) | 2008-06-10 | 2009-12-17 | Central Northern Adelaide Health Service | Treatment of diabetes and complications thereof and related disorders |
US20140024713A1 (en) * | 2008-06-19 | 2014-01-23 | University Of Utah Research Foundation | Use of nitrated lipids for treatment of side effects of toxic medical therapies |
WO2009155439A2 (en) | 2008-06-19 | 2009-12-23 | University Of Utah Research Foundation | Use of nitrated lipids for treatment of side effects of toxic medical therapies |
WO2010012777A1 (en) | 2008-07-29 | 2010-02-04 | Nerviano Medical Sciences S.R.L. | THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT |
US9139554B2 (en) | 2008-10-09 | 2015-09-22 | Tekmira Pharmaceuticals Corporation | Amino lipids and methods for the delivery of nucleic acids |
AU2009334476B2 (en) * | 2008-12-31 | 2013-08-29 | Nitromega Corp. | Nutraceuticals containing nitro fatty acids |
US8937194B2 (en) * | 2008-12-31 | 2015-01-20 | Nitromega Corp. | Topical compositions containing nitro fatty acids |
US20100286272A1 (en) | 2009-05-08 | 2010-11-11 | Perricone Nicholas V | Methods Of Use Of Nitroalkene Compositions In Dermatologic Applications |
US20100286271A1 (en) | 2009-05-08 | 2010-11-11 | Perricone Nicholas V | Nitro-alkyl Compound Compositions |
US20100286257A1 (en) | 2009-05-08 | 2010-11-11 | Perricone Nicholas V | Methods Of Use Of Nitroalkane Compositions In Dermatologic Applications To Prevent or Treat Skin Aging |
JP2013500275A (en) | 2009-07-29 | 2013-01-07 | フェノメノーム ディスカバリーズ インク | Hydroxy fatty acid compounds and their use for disease treatment and diagnosis |
EP2459189A4 (en) | 2009-07-31 | 2013-01-16 | Univ Pittsburgh | Fatty acids as anti-inflammatory agents |
EP2483233A4 (en) | 2009-10-02 | 2013-08-14 | Complexa Inc | Heteroatom containing substituted fatty acids |
CN102822152A (en) | 2009-11-09 | 2012-12-12 | 诺瓦德克斯制药股份有限公司 | Novel 1,3-oxazolidine compounds and their use as renin inhibitors |
WO2011098746A1 (en) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
WO2011113507A2 (en) * | 2010-03-15 | 2011-09-22 | Ulrich Dietz | Use of nitrocarboxylic acids for the treatment, diagnosis and prophylaxis of aggressive healing patterns |
JP2013526865A (en) | 2010-05-13 | 2013-06-27 | ニトロメガ コーポレーション | Nitro fatty acids, neuroprotection and / or suppression of cognitive decline |
JP2013534930A (en) | 2010-06-28 | 2013-09-09 | コンプレクサ,インコーポレイテッド | Multi-component formulation for the treatment of diabetes |
EP2744491B1 (en) * | 2011-08-19 | 2020-07-29 | The University of Utah Research Foundation | Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system |
US9271952B2 (en) | 2011-10-11 | 2016-03-01 | Complexa, Inc. | Compositions and methods for treating nephropathy |
DE102012008730A1 (en) | 2011-12-02 | 2013-06-06 | Dr. Budz GmbH | Oral composition, useful e.g. as dietary supplement, comprises monounsaturated fatty acids comprising oleic acid e.g. oleic acid-((Z)-9-octadecenoic acid) in combination with peptides consisting of specific amino acids and/or antioxidant |
CA2863765A1 (en) | 2012-02-03 | 2013-08-08 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Fatty acids as anti-inflammatory agents |
US20140271844A1 (en) * | 2013-03-15 | 2014-09-18 | Nitromega Corp. | Compositions containing nitro fatty acids |
CN105339006A (en) | 2013-05-10 | 2016-02-17 | 尼特罗米加公司 | Nutritional or dietary supplements containing fatty acids and nitrite |
US20150051283A1 (en) | 2013-06-14 | 2015-02-19 | Complexa, Inc. | Composition and method for inhibition of pkng from mycobacterium tuberculosis |
WO2015073527A1 (en) | 2013-11-12 | 2015-05-21 | Complexa, Inc. | Nitroalkene tocopherols and analogs thereof for use in the treatment and prevention of inflammation related conditions |
WO2016161285A1 (en) * | 2015-04-02 | 2016-10-06 | Aobiome Llc | Production of nitro-fatty acids and nitro-hydrocarbons by ammonia oxidizing bacteria |
KR20180098222A (en) * | 2015-10-02 | 2018-09-03 | 컴플렉사, 인코포레이티드 | Prevention, treatment and reversal of diseases using therapeutically effective amounts of activated fatty acids |
-
2016
- 2016-10-03 KR KR1020187012337A patent/KR20180098222A/en not_active Application Discontinuation
- 2016-10-03 WO PCT/US2016/055206 patent/WO2017059451A1/en active Application Filing
- 2016-10-03 US US15/283,887 patent/US10537541B2/en not_active Expired - Fee Related
- 2016-10-03 AU AU2016331314A patent/AU2016331314A1/en not_active Abandoned
- 2016-10-03 JP JP2018536704A patent/JP2018529779A/en not_active Withdrawn
- 2016-10-03 SG SG10201913953UA patent/SG10201913953UA/en unknown
- 2016-10-03 CA CA3000842A patent/CA3000842A1/en not_active Abandoned
- 2016-10-03 EA EA201890859A patent/EA201890859A1/en unknown
- 2016-10-03 EP EP16852846.1A patent/EP3355879A4/en not_active Withdrawn
- 2016-10-03 CN CN201680070797.XA patent/CN108430466A/en active Pending
- 2016-10-03 IL IL258476A patent/IL258476B2/en unknown
- 2016-10-03 CR CR20180246A patent/CR20180246A/en unknown
- 2016-10-03 CN CN202110744035.6A patent/CN113440506A/en active Pending
- 2016-10-03 MX MX2018004043A patent/MX2018004043A/en unknown
- 2016-10-03 BR BR112018006687A patent/BR112018006687A2/en not_active Application Discontinuation
- 2016-10-03 IL IL297844A patent/IL297844A/en unknown
-
2018
- 2018-03-29 CL CL2018000835A patent/CL2018000835A1/en unknown
- 2018-04-27 CO CONC2018/0004576A patent/CO2018004576A2/en unknown
-
2019
- 2019-01-29 HK HK19101519.9A patent/HK1259031A1/en unknown
- 2019-10-18 US US16/657,028 patent/US20200046669A1/en not_active Abandoned
-
2021
- 2021-03-19 US US17/207,380 patent/US20220000824A1/en not_active Abandoned
- 2021-07-14 AU AU2021205027A patent/AU2021205027A1/en not_active Abandoned
- 2021-08-27 JP JP2021139287A patent/JP2021183640A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL297844A (en) | 2023-01-01 |
EP3355879A1 (en) | 2018-08-08 |
AU2016331314A1 (en) | 2018-05-17 |
AU2021205027A1 (en) | 2021-08-12 |
WO2017059451A1 (en) | 2017-04-06 |
EA201890859A1 (en) | 2018-11-30 |
CO2018004576A2 (en) | 2018-07-19 |
JP2018529779A (en) | 2018-10-11 |
CN108430466A (en) | 2018-08-21 |
US10537541B2 (en) | 2020-01-21 |
US20200046669A1 (en) | 2020-02-13 |
CA3000842A1 (en) | 2017-04-06 |
IL258476B2 (en) | 2023-04-01 |
CL2018000835A1 (en) | 2018-09-14 |
HK1259031A1 (en) | 2019-11-22 |
JP2021183640A (en) | 2021-12-02 |
BR112018006687A2 (en) | 2018-10-09 |
US20170095437A1 (en) | 2017-04-06 |
KR20180098222A (en) | 2018-09-03 |
CR20180246A (en) | 2018-11-22 |
IL258476A (en) | 2018-06-28 |
IL258476B (en) | 2022-12-01 |
EP3355879A4 (en) | 2019-05-22 |
US20220000824A1 (en) | 2022-01-06 |
CN113440506A (en) | 2021-09-28 |
MX2018004043A (en) | 2018-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1259031A1 (en) | Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids | |
EP3349783C0 (en) | Compositions and methods relating to the treatment of diseases | |
EP3253451A4 (en) | Diagnosis and treatment of chronic pain | |
EP3130582B8 (en) | Compound having immune disease treatment effect and use thereof | |
ZA201804950B (en) | Indolinones compounds and their use in the treatment of fibrotic diseases | |
HK1249865B (en) | Treatment of pain | |
EP3440045A4 (en) | Prevention, treatment and reversal of disease using therapeutically effective amounts of dicarboxylic acid compounds | |
FR3044227B1 (en) | AMINOPHOSPHINE DERIVATIVES FOR THE PREVENTION AND TREATMENT OF EYE PAIN | |
HK1252359A1 (en) | Combination of trazodone and gabapentin for the treatment of pain | |
EP3137097C0 (en) | Treatment and prevention of alzheimer's disease (ad) | |
EP3377062C0 (en) | Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases | |
LT3137093T (en) | Treatment and prevention of alzheimer`s disease (ad) | |
PL3137094T3 (en) | Treatment and prevention of alzheimer's disease (ad) | |
FR3016881B1 (en) | TREATMENT OF DEGENERESCENCES AND PHOTO-INDUCED LESIONS OF THE RETINA | |
GB201621398D0 (en) | Treatment of emt-associated disease | |
GB201516437D0 (en) | Compositions and methods relating to the treatment of disease | |
SG11201705889VA (en) | Prevention or Treatment of Uratic or Gouty Diseases | |
GB201504413D0 (en) | Treatment of disease | |
GB201522828D0 (en) | Prevention and treatment of glaucoma | |
GB201516303D0 (en) | Compositions and methods relating to the treatment of diseases | |
EP3188744A4 (en) | Methods for treatment and prevention of vascular disease |